Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (5393)	1/10/2002 1:06:21 PM
From: Biomaven	Read Replies (1) of 52153

Wilder, I've done well with VGIN in the past (I owned it starting back in 1999) but (fortunately) haven't owned it for quite a while. I suspect they are currently in the post-approval doldrums that happens when the eagerly-awaited revenues don't match up to the dream. It's often a very good time to buy, particularly with a product that you think will do well in the long run but might be slow to catch on. I do think that their product works and will be ever-more needed as more resistant strains spread and new drugs are developed. I have no idea what their margins are like, though - this was always a concern in their early years. I haven't looked at them (and their phenotyping and genotyping competition) recently, but was intending to do so. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next